Amgen Inc drugs

12 results
  • amjevita - adalimumab - atto injection

    (Adalimumab-Atto)
    Amgen Inc
    TNF blocker for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and eligible pediatric patients.
  • bkemv - eculizumab - aeeb injection, solution, concentrate

    (Eculizumab-Aeeb)
    Amgen Inc
    BKEMV is a complement inhibitor indicated for paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in AChR antibody-positive adults. Not indicated for STEC-HUS.
  • imlygic - talimogene laherparepvec injection, suspension

    (Talimogene Laherparepvec)
    Amgen Inc
    IMLYGIC is an oncolytic viral therapy for local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in melanoma patients who have had a recurrence after initial surgery. It has not been shown to improve overall survival or affect visceral metastases.
  • lumakras - sotorasib tablet, coated

    (Sotorasib)
    Amgen Inc
    Lumakras treats adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (after at least one prior therapy) and KRAS G12C-mutated metastatic colorectal cancer (combined with panitumumab, after prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy).
  • parsabiv - etelcalcetide injection, solution

    (Etelcalcetide)
    Amgen Inc
    PARSABIV treats secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis. Not recommended for parathyroid carcinoma, primary hyperparathyroidism, or chronic kidney disease patients not on hemodialysis.